Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis suffers as data again link Lantus with cancer risk

This article was originally published in Scrip

Executive Summary

Sanofi-Aventis's blockbuster long-acting insulin analogue Lantus (insulin glargine) is associated with an increased cancer incidence, concludes a recent research article published in Diabetes Care. The charge comes nearly exactly one year since the French drug firm found itself defending against the same charge, made in series of Diabetologia articles (, 30 June 2009).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts